U. Fabry

1.2k total citations
27 papers, 916 citations indexed

About

U. Fabry is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine. According to data from OpenAlex, U. Fabry has authored 27 papers receiving a total of 916 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Pathology and Forensic Medicine. Recurrent topics in U. Fabry's work include Medical Imaging Techniques and Applications (7 papers), Radiomics and Machine Learning in Medical Imaging (5 papers) and Lymphoma Diagnosis and Treatment (4 papers). U. Fabry is often cited by papers focused on Medical Imaging Techniques and Applications (7 papers), Radiomics and Machine Learning in Medical Imaging (5 papers) and Lymphoma Diagnosis and Treatment (4 papers). U. Fabry collaborates with scholars based in Germany, Switzerland and Austria. U. Fabry's co-authors include R. Osieka, Thomas Efferth, U. Cremerius, Michael Zimny, J. Neuerburg, Udalrich Buell, Rolf W. Günther, Joachim E. Wildberger, Marcus Blaum and Andreas H. Mahnken and has published in prestigious journals such as Journal of Leukocyte Biology, Cancer Letters and American Journal of Roentgenology.

In The Last Decade

U. Fabry

27 papers receiving 896 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
U. Fabry Germany 18 302 297 219 185 180 27 916
Hyunee Yim South Korea 21 145 0.5× 181 0.6× 176 0.8× 160 0.9× 260 1.4× 66 1.1k
Örjan Nordle Sweden 15 133 0.4× 174 0.6× 342 1.6× 260 1.4× 253 1.4× 26 1.1k
N. I. Nissen Denmark 19 196 0.6× 64 0.2× 157 0.7× 373 2.0× 252 1.4× 58 1.0k
N A Brophy United States 10 145 0.5× 111 0.4× 111 0.5× 759 4.1× 429 2.4× 13 1.2k
E H Cooper United Kingdom 20 109 0.4× 98 0.3× 194 0.9× 523 2.8× 310 1.7× 39 1.2k
A Morell United States 20 77 0.3× 122 0.4× 268 1.2× 183 1.0× 411 2.3× 56 1.2k
Richard K. Desser United States 19 218 0.7× 46 0.2× 354 1.6× 428 2.3× 115 0.6× 30 995
Huiqiang Huang China 16 321 1.1× 52 0.2× 90 0.4× 352 1.9× 218 1.2× 79 819
Pooja Advani United States 17 100 0.3× 81 0.3× 107 0.5× 358 1.9× 219 1.2× 67 799
Shingo Tanaka Japan 19 61 0.2× 93 0.3× 207 0.9× 125 0.7× 177 1.0× 68 904

Countries citing papers authored by U. Fabry

Since Specialization
Citations

This map shows the geographic impact of U. Fabry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Fabry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Fabry more than expected).

Fields of papers citing papers by U. Fabry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U. Fabry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Fabry. The network helps show where U. Fabry may publish in the future.

Co-authorship network of co-authors of U. Fabry

This figure shows the co-authorship network connecting the top 25 collaborators of U. Fabry. A scholar is included among the top collaborators of U. Fabry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with U. Fabry. U. Fabry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lorenzen, Johann, et al.. (2004). Acute myeloid leukaemia with t(8;21) associated with “occult” mastocytosis. Report of an unusual case and review of the literature. Journal of Clinical Pathology. 57(3). 324–328. 44 indexed citations
2.
Galm, Oliver, U. Fabry, Thomas Efferth, & R. Osieka. (2002). Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression. Cancer Letters. 187(1-2). 143–151. 8 indexed citations
3.
4.
Mahnken, Andreas H., Joachim E. Wildberger, Gerald Gehbauer, et al.. (2002). Multidetector CT of the Spine in Multiple Myeloma: Comparison with MR Imaging and Radiography. American Journal of Roentgenology. 178(6). 1429–1436. 138 indexed citations
5.
Efferth, Thomas, U. Fabry, & R. Osieka. (2001). Induction of apoptosis, depletion of glutathione, and DNA damage by extracorporeal photochemotherapy and psoralen with exposure to UV light in vitro.. PubMed. 21(4A). 2777–83. 13 indexed citations
6.
Galm, Oliver, U. Fabry, Gerhard Adam, & R. Osieka. (2001). Pneumatosis intestinalis following Cytotoxic or Immunosuppressive Treatment. Digestion. 64(2). 128–132. 31 indexed citations
7.
Maywald, Ole, Oliver Galm, U. Fabry, E. Kohne, & R. Osieka. (2001). Ungewöhnliche Ursache einer Erythrozytose bei einer 23-jährigen Erstgebärenden in der 22. Schwangerschaftswoche. Medizinische Klinik. 96(1). 45–49. 2 indexed citations
8.
Efferth, Thomas, U. Fabry, & R. Osieka. (2001). DNA damage and apoptosis in mononuclear cells from glucose-6-phosphate dehydrogenase-deficient patients (G6PD Aachen variant) after UV irradiation. Journal of Leukocyte Biology. 69(3). 340–342. 18 indexed citations
9.
Efferth, Thomas, U. Fabry, & R. Osieka. (2000). Leptin contributes to the protection of human leukemic cells from cisplatinum cytoxicity.. PubMed. 20(4). 2541–6. 9 indexed citations
10.
Efferth, Thomas, U. Fabry, & R. Osieka. (2000). Damage of the kinesin heavy chain gene contributes to the antagonism of cisplatin and paclitaxel.. PubMed. 20(5A). 3211–9. 7 indexed citations
11.
Cremerius, U., U. Fabry, Michael Zimny, et al.. (1999). [Clinical value of FDG PET for therapy monitoring of malignant lymphoma--results of a retrospective study in 72 patients].. PubMed. 38(1). 24–30. 38 indexed citations
12.
Cremerius, U., U. Fabry, J. Neuerburg, et al.. (1998). Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nuclear Medicine Communications. 19(11). 1055–1064. 113 indexed citations
13.
Efferth, Thomas, U. Fabry, & R. Osieka. (1997). Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia. 11(7). 1180–1186. 52 indexed citations
14.
Neuerburg, J., U. Fabry, U. Cremerius, et al.. (1997). Vergleich der Befunde von 18-FDG- PET und CT beim prätherapeutischen Staging maligner Lymphome. Nuklearmedizin - NuclearMedicine. 36(7). 234–239. 27 indexed citations
15.
Efferth, Thomas, U. Fabry, & R. Osieka. (1996). Anti-Fas/Apo-1 Monoclonal Antibody CH-11 Depletes Glutathione and Kills Multidrug-Resistant Human Leukemic Cells. Blood Cells Molecules and Diseases. 22(1). 2–9. 18 indexed citations
16.
Efferth, Thomas, et al.. (1996). Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs.. PubMed. 46(2). 196–200. 90 indexed citations
17.
Reinert, Ralf René, Norbert Schnitzler, Gerhard Haase, et al.. (1995). Recurrent bacteremia due toBrevibacterium casei in an immunocompromised patient. European Journal of Clinical Microbiology & Infectious Diseases. 14(12). 1082–1085. 26 indexed citations
18.
Efferth, Thomas, et al.. (1995). Increased induction of apoptosis in mononuclear cells of a glucose-6-phosphate dehydrogenase deficient patient. Journal of Molecular Medicine. 73(1). 47–49. 27 indexed citations
19.
Efferth, Thomas, et al.. (1995). Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells. Journal of Cancer Research and Clinical Oncology. 121(11). 648–656. 34 indexed citations
20.
Körholz, Dieter, V. Wahn, Rüdiger von Kries, U. Fabry, & U. Göbel. (1986). Bedeutung von Immunkomplexen bei Kindern mit schwerer Hämophilie A unter Substitutionsbehandlung mit Faktor VIII-Konzentration. Klinische Pädiatrie. 198(4). 306–311. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hyunee Yim Breakdown of academic impact, for papers by Örjan Nordle Breakdown of academic impact, for papers by N. I. Nissen Breakdown of academic impact, for papers by N A Brophy Breakdown of academic impact, for papers by E H Cooper Breakdown of academic impact, for papers by A Morell Breakdown of academic impact, for papers by Richard K. Desser Breakdown of academic impact, for papers by Huiqiang Huang Breakdown of academic impact, for papers by Pooja Advani Breakdown of academic impact, for papers by Shingo Tanaka
Rankless by CCL
2026